European Archives - Page 518 of 1164 - European Medical Journal

Key pharma trends from Cannes Lions

In this episode, Helena and Marc are joined by Claire Gillis, CEO, VMLY&R Health, to discuss the health and pharma highlights from the recent Cannes Lions.

Vaccines and sustainability focus for GSK

In its annual Palio meeting, GSK discusses the growing threat to human health from infectious disease with a group of experts in immunology, vaccinology and epidemiology.

Treatment Landscape and Emerging Therapies in Oesophageal Cancer: Interviews with Two Key Opinion Leaders

EMJ conducted interviews in February 2022 with two key opinion leaders (KOL), Zachary Wilmer Reichenbach, who works in the Department of…

EMJ Oncology 10 [Supplement 8] 2022

EMJ had the pleasure of interviewing two leading specialists within the field of oncology and oesophageal cancer, Zachary Wilmer Reichenbach, Department of Gastroenterology…

Global health agencies collaborate to ease Ebola outbreak

CEPI, Gavi and WHO have announced a collective effort to support the Ugandan Government’s response to the recent Ebolavirus outbreak.

Urology

Laser Removal of Ureteral Stent Suture via Ureteroscopy

In this case, retrograde ureteroscopy with holmium laser on the retained suture proved an effective treatment in the removal of the stent.

The latest advances in prostate cancer research

On the final day of EAU22 in Amsterdam, experts stepped away from the action to present highlights in prostate cancer treatment from this year’s congress.

Predicting Type 2 Diabetes Remission in Patients of Gastric Bypass

Blood ceramide levels could help predict whether patients with Type 2 diabetes who undergo gastric bypass surgery will experience remission…

The Value of Evidence-Based Medicine

In this week’s episode, Jonathan is joined by Uwe Gudat, Chief Medical Officer, Aretaeus Sàrl, Geneva, Switzerland.

Editor’s Pick: Impact of COVID-19 on Diagnostic Delay in Rare Disease

Rare diseases are individually rare but collectively common, with a combined prevalence of 3.5–5.9%. A common feature of many diseases is a substantial delay in patients receiving a correct diagnosis; this protracted path to diagnosis is termed ‘the diagnostic odyssey’.